Summary

Eligibility
for females ages 21 years and up (full criteria)
Location
at UCLA
Dates
study started
study ends around
Principal Investigator
by John A. Glaspy, MD (ucla)
Headshot of John A. Glaspy
John A. Glaspy

Description

Summary

This phase II trial studies the effect of pembrolizumab on cervical intraepithelial neoplasia. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Official Title

A Phase II Open-Label, Single Arm Pilot Study to Evaluate the Safety and Efficacy of Pembrolizumab for High-Grade Cervical Intraepithelial Neoplasia

Details

Keywords

Cervical Intraepithelial Neoplasia, Cervical Squamous Cell Carcinoma In Situ, Cervical Squamous Intraepithelial Neoplasia 2, Neoplasms, Carcinoma in Situ, Uterine Cervical Dysplasia, Squamous Intraepithelial Lesions of the Cervix, Pembrolizumab

Eligibility

Location

  • University of California at Los Angeles / Jonsson Comprehensive Cancer Center accepting new patients
    Los Angeles California 90095 United States

Lead Scientist at University of California Health

  • John A. Glaspy, MD (ucla)
    Dr. John A. Glaspy holds the Simms/Mann Family Foundation Chair in Integrative Oncology.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Jonsson Comprehensive Cancer Center
ID
NCT04712851
Phase
Phase 2 research study
Study Type
Interventional
Participants
Expecting 25 study participants
Last Updated